Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer

Katharina Boehm, Paolo Dell’Oglio, Zhe Tian, Umberto Capitanio, Felix K H Chun, Derya Tilki, Axel Haferkamp, Fred Saad, Francesco Montorsi, Markus Graefen, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. Patients and methods: We relied on the SEER–Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. Results: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). Conclusion: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalWorld Journal of Urology
DOIs
Publication statusAccepted/In press - Oct 28 2016

Fingerprint

Life Expectancy
Comorbidity
Prostatic Neoplasms
Mortality
Brachytherapy
Prostatectomy
Androgens
Observation
Therapeutics
Radiation
Databases
Incidence

Keywords

  • Competing risks analysis
  • Elderly patients
  • Life expectancy
  • Mortality
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. / Boehm, Katharina; Dell’Oglio, Paolo; Tian, Zhe; Capitanio, Umberto; Chun, Felix K H; Tilki, Derya; Haferkamp, Axel; Saad, Fred; Montorsi, Francesco; Graefen, Markus; Karakiewicz, Pierre I.

In: World Journal of Urology, 28.10.2016, p. 1-6.

Research output: Contribution to journalArticle

Boehm, Katharina ; Dell’Oglio, Paolo ; Tian, Zhe ; Capitanio, Umberto ; Chun, Felix K H ; Tilki, Derya ; Haferkamp, Axel ; Saad, Fred ; Montorsi, Francesco ; Graefen, Markus ; Karakiewicz, Pierre I. / Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. In: World Journal of Urology. 2016 ; pp. 1-6.
@article{3f2690d694ef48abbf0aeeeea4db2e35,
title = "Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer",
abstract = "Introduction: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. Patients and methods: We relied on the SEER–Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5{\%}), BT (13.9{\%}), EBRT (21.4{\%}), ADT alone (16.3{\%}) or observation (32.8{\%}). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. Results: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). Conclusion: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.",
keywords = "Competing risks analysis, Elderly patients, Life expectancy, Mortality, Prostate cancer, Radical prostatectomy",
author = "Katharina Boehm and Paolo Dell’Oglio and Zhe Tian and Umberto Capitanio and Chun, {Felix K H} and Derya Tilki and Axel Haferkamp and Fred Saad and Francesco Montorsi and Markus Graefen and Karakiewicz, {Pierre I.}",
year = "2016",
month = "10",
day = "28",
doi = "10.1007/s00345-016-1963-7",
language = "English",
pages = "1--6",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer

AU - Boehm, Katharina

AU - Dell’Oglio, Paolo

AU - Tian, Zhe

AU - Capitanio, Umberto

AU - Chun, Felix K H

AU - Tilki, Derya

AU - Haferkamp, Axel

AU - Saad, Fred

AU - Montorsi, Francesco

AU - Graefen, Markus

AU - Karakiewicz, Pierre I.

PY - 2016/10/28

Y1 - 2016/10/28

N2 - Introduction: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. Patients and methods: We relied on the SEER–Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. Results: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). Conclusion: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.

AB - Introduction: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. Patients and methods: We relied on the SEER–Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. Results: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). Conclusion: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.

KW - Competing risks analysis

KW - Elderly patients

KW - Life expectancy

KW - Mortality

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84992727771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992727771&partnerID=8YFLogxK

U2 - 10.1007/s00345-016-1963-7

DO - 10.1007/s00345-016-1963-7

M3 - Article

AN - SCOPUS:84992727771

SP - 1

EP - 6

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -